Immunisation againstNeisseria meningitidisin those at
risk of exposure to prevent invasive disease
▶BY INTRAMUSCULAR INJECTION
▶Child 3–11 months: 0. 5 mL every month for 2 doses, dose
preferably injected into deltoid region
▶Child 1–17 years: 0. 5 mL for 1 dose, dose preferably
injected into deltoid region
Patients attending university for the first time (who have
not received the routine meningococcal A, C, W 135 , and
Y conjugate vaccine over the age of 10 years)
▶BY INTRAMUSCULAR INJECTION
▶Child 16–17 years: 0. 5 mL for 1 dose
NIMENRIX®
Primary immunisation againstNeisseria meningitidis
▶BY INTRAMUSCULAR INJECTION
▶Child 13–15 years: 0. 5 mL for 1 dose, to be injected
preferably into deltoid region
Immunisation againstNeisseria meningitidisin an
unimmunised patient
▶BY INTRAMUSCULAR INJECTION
▶Child 10–17 years: 0. 5 mL for 1 dose, booster dose is not
required
Immunisation againstNeisseria meningitidisin those at
risk of exposure
▶BY INTRAMUSCULAR INJECTION
▶Child 1–17 years: 0. 5 mL for 1 dose, to be injected
preferably into deltoid region (or anterolateral thigh in
child 12 – 23 months), then 0. 5 mL after 1 year if
required for 1 dose, second dose should be considered
in those who continue to be at risk ofNeisseria
meningitidisserogroup A infection
Patients attending university for the first time (who have
not received the routine meningococcal A, C, W 135 , and
Y conjugate vaccine over the age of 10 years)
▶BY INTRAMUSCULAR INJECTION
▶Child 16–17 years: 0. 5 mL for 1 doselUNLICENSED USE
MENVEO®Menveo®is not licensed for use in children
under 2 years.lSIDE-EFFECTS
▶Common or very commonDrowsiness
▶UncommonCrying.insomnia.numbness.pain in
extremity
▶Frequency not knownExtensive swelling of vaccinated limb
lMEDICINAL FORMS
There can be variation in the licensing of different medicines
containing the same drug.
Powder and solvent for solution for injection
▶Menveo(GlaxoSmithKline UK Ltd)
Menveo vaccine powder and solvent for solution for injection 0. 5 ml
vials| 1 vialP£ 30. 00
▶Nimenrix(Pfizer Ltd)
Nimenrix vaccine powder and solvent for solution for injection 0. 5 ml
pre-filled syringes| 1 pre-filled disposable injectionP£ 30. 00
eiiiiF 788
Pneumococcal polysaccharide
conjugate vaccine (adsorbed)
lINDICATIONS AND DOSE
PREVENAR 13®
Primary immunisation against pneumococcal infection
(first dose)
▶BY INTRAMUSCULAR INJECTION
▶Child 2 months: 0. 5 mL for 1 dose, anterolateral thigh is
preferred site of injection in infantsPrimary immunisation against pneumococcal infection
(second dose)
▶BY INTRAMUSCULAR INJECTION
▶Child 4 months: 0. 5 mL for 1 dose, anterolateral thigh is
preferred site of injection in infants
Primary immunisation against pneumococcal infection
(booster dose)
▶BY INTRAMUSCULAR INJECTION
▶Child 12–13 months: 0. 5 mL for 1 dose, anterolateral
thigh is preferred site of injection in infants
Immunisation against pneumococcal infection (in patients
who have not been vaccinated or not completed the
primary course)
▶BY INTRAMUSCULAR INJECTION
▶Child 12 months–4 years: 0. 5 mL for 1 dose, deltoid
muscle is preferred site of injection in young children;
anterolateral thigh is preferred site in infants
Immunisation against pneumococcal infection, in
immunocompromised or asplenic patients or patients
with splenic dysfunction (who have not been vaccinated
or not completed the primary course)
▶BY INTRAMUSCULAR INJECTION
▶Child 12 months–4 years: 0. 5 mL every 2 months for
2 doses, deltoid muscle is preferred site of injection in
young children; anterolateral thigh is preferred site in
infants
SYNFLORIX®
Immunisation against pneumococcal infection
▶BY INTRAMUSCULAR INJECTION
▶Child 6 weeks–4 years:Deltoid muscle is preferred site
of injection in young children; anterolateral thigh is
preferred site in infants (consult product literature)lUNLICENSED USE
PREVENAR 13®The dose in BNF publications may differ
from that in product literature.
lSIDE-EFFECTS
▶Common or very commonDrowsiness
▶UncommonApnoea.crying abnormal.extensive swelling
of vaccinated limb
▶Rare or very rareAngioedema.hypotonic-
hyporesponsiveness episode.Kawasaki disease.seizure
lPRESCRIBING AND DISPENSING INFORMATION
PREVENAR 13®Available as part of childhood
immunisation schedule from ImmFormwww.immform.dh.
gov.uk.lMEDICINAL FORMS
There can be variation in the licensing of different medicines
containing the same drug.
Suspension for injection
▶Prevenar(Pfizer Ltd)
Prevenar 13 vaccine suspension for injection 0. 5 ml pre-filled syringes
| 1 pre-filled disposable injectionP£ 49. 10 | 10 pre-filled
disposable injectionP£ 491. 00
▶Synflorix(GlaxoSmithKline UK Ltd)
Synflorix vaccine suspension for injection 0. 5 ml pre-filled syringes|
1 pre-filled disposable injectionP£ 27. 60eiiiiF 788Pneumococcal polysaccharide vaccine
lINDICATIONS AND DOSE
Immunisation against pneumococcal infection
▶BY INTRAMUSCULAR INJECTION, OR BY SUBCUTANEOUS
INJECTION
▶Child 2–17 years: 0. 5 mL for 1 dose continued→BNFC 2018 – 2019 Vaccination 793
Vaccines14